Definitive Healthcare Corp. (NASDAQ:DH) Receives Consensus Recommendation of “Hold” from Analysts

Definitive Healthcare Corp. (NASDAQ:DH) has earned a consensus rating of “Hold” from the eleven research firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $5.72.

Several equities research analysts have recently commented on the stock. Stephens initiated coverage on shares of Definitive Healthcare in a research note on Friday, December 20th. They issued an “equal weight” rating and a $5.00 target price on the stock. Needham & Company LLC restated a “hold” rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. Finally, Barclays reaffirmed an “underweight” rating and set a $4.00 price objective on shares of Definitive Healthcare in a research note on Monday, January 13th.

Definitive Healthcare Stock Performance

NASDAQ:DH opened at $4.71 on Thursday. The firm’s 50-day moving average is $4.34 and its 200-day moving average is $4.47. The company has a market cap of $544.10 million, a price-to-earnings ratio of -1.52, a PEG ratio of 2.96 and a beta of 1.41. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49. Definitive Healthcare has a 52-week low of $3.19 and a 52-week high of $10.62.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.03). The firm had revenue of $62.70 million for the quarter, compared to the consensus estimate of $61.66 million. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. During the same quarter in the prior year, the firm posted $0.01 earnings per share. Equities research analysts anticipate that Definitive Healthcare will post 0.15 earnings per share for the current year.

Insider Buying and Selling

In other news, insider William Moschella sold 45,000 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $4.70, for a total value of $211,500.00. Following the sale, the insider now owns 433,830 shares of the company’s stock, valued at $2,039,001. The trade was a 9.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 14.84% of the company’s stock.

Institutional Trading of Definitive Healthcare

Several institutional investors and hedge funds have recently added to or reduced their stakes in DH. Rhumbline Advisers raised its stake in Definitive Healthcare by 19.7% in the second quarter. Rhumbline Advisers now owns 83,751 shares of the company’s stock valued at $457,000 after buying an additional 13,764 shares during the period. Renaissance Technologies LLC raised its stake in Definitive Healthcare by 50.5% in the 2nd quarter. Renaissance Technologies LLC now owns 28,900 shares of the company’s stock valued at $158,000 after acquiring an additional 9,700 shares during the period. Hsbc Holdings PLC acquired a new stake in Definitive Healthcare during the 2nd quarter valued at $127,000. Canada Pension Plan Investment Board bought a new position in Definitive Healthcare during the second quarter worth $109,000. Finally, Marshall Wace LLP acquired a new position in shares of Definitive Healthcare in the second quarter valued at $1,535,000. 98.67% of the stock is owned by institutional investors.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.